Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.36 |
| ▸ | RELA | Q04206 | 6/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886350 | 0.96 | CYP1A2 (0.39) | CYP1A2CYP2D6ALPGCYP2C19SMN1; SMN2 | |
| SCHEMBL18505012 | 0.89 | L3MBTL1 (0.39) | L3MBTL1NFKB1NFKB2RELATDP1 | |
| SCHEMBL12377772 | 0.89 | L3MBTL1 (0.39) | L3MBTL1NFKB1NFKB2RELATDP1 | |
| SCHEMBL74057 | 0.89 | L3MBTL1 (0.39) | L3MBTL1NFKB1NFKB2RELATDP1 | |
| SCHEMBL13742957 | 0.85 | CYP1A2 (0.46) | CYP1A2CYP2D6ALPGCYP2C19SMN1; SMN2 | |
| SCHEMBL14271046 | 0.79 | L3MBTL1 (0.51) | CYP1A2CYP2D6ALPGCYP2C19SMN1; SMN2 | |
| SCHEMBL12634455 | 0.77 | PRKCG (0.43) | DRD2HPGD | |
| SCHEMBL16650717 | 0.76 | CYP1A2 (0.43) | CYP1A2CYP2D6ALPGCYP2C19SMN1; SMN2 | |
| SCHEMBL9882973 | 0.75 | SSTR2 (0.35) | L3MBTL1NFKB1NFKB2RELATDP1 | |
| SCHEMBL14046825 | 0.75 | SSTR2 (0.35) | L3MBTL1NFKB1NFKB2RELATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42013-E1 | Macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2010-12-28 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | CYP1A2 2064/4885CYP2D6 2748/4885ALPG 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.